Date: 2016-01-11
Type of information: Financing round
Company: Novimmune (Switzerland)
Investors:
Amount: CHF 30 million ($29.8 million - €27.6 million)
Funding type: financing round
Planned used:
Others: * On January 11, 2016, Novimmune announced it has completed a CHF 30 million ($29.8 million - €27.6 million)
Therapeutic area: Cancer - Oncology - Rare diseases - Immunological diseases
